Ключевые слова:
полиморфизма rs2279115 гена BCL2, Рh–позитивные и Рh–негативные МПН, экологически неблагоприятный регион, Хорезмская область, риск развития МПН.Библиографические ссылки
Al–Amer OM, Mir R, Hamadi A, Alasseiri MI, Altayar MA, AlZamzami W, Moawadh M, Alatawi S, Niaz HA, Oyouni AAA, Alzahrani OR, Alatwi HE, Albalawi AE, Alsharif KF, Albrakati A, Hawsawi YM. Antiapoptotic Gene Genotype and Allele Variations and the Risk of Lymphoma. Cancers (Basel). 2023 Feb 5;15(4):1012. doi: 10.3390/cancers15041012.
Arber D.A., Orazi A., Hasserjian R.P., Borowitz M.J., Calvo K.R., Kvasnicka H.M., Wang S.A., Bagg A., Barbui T., Branford S., et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data. Blood. 2022; 140:1200–1228. doi: 10.11 82/blood.2022015850.
Chatterjee K, De S, Deb Roy S, Sahu SK, Chakraborty A, Ghatak S, Das N, Mal S, Roy Chattopadhyay N, Das P, Reddy RR, Mukherjee S, Das AK, Puii Z, Zomawia E, Singh YI, Tsering S, Riba K, Rajasubramaniam S, Suryawanshi AR, Choudhuri T. BAX –248 G>A and BCL2 –938 C>A Variant Lowers the Survival in Patients with Nasopharyngeal Carcinoma and Could be Associated with Tissue–Specific Malignancies: A Multi–Method Approach. Asian Pac J Cancer Prev. 2021 Apr 1;22(4):1171–1181. doi: 10.31557/APJCP.2021.22.4.1171.
Cingeetham A, Vuree S, Dunna NR, Gorre M, Nanchari SR, Edathara PM, Meka P, Annamaneni S, Digumarthi R, Sinha S, Satti V. Influence of BCL2–938C>A and BAX–248G>A promoter polymorphisms in the development of AML: case–control study from South India. Tumour Biol. 2015 Sep;36(10):7967–76. doi: 10.1007/s13277–015–3457–4.
Giraldo–Rincón AI, Naranjo Molina S, Gomez–Lopera N, Aguirre Acevedo D, Ucroz Benavidez A, Gálvez Cárdenas K, Cuellar Ambrosí F, Torres JD, Ospina S, Palacio K, Gaviria Jaramillo L, Muñeton CM, Vasquez Palacio G. JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR–ABL Negative Myeloproliferative Neoplasms. Colomb Med (Cali). 2023 Sep 30;54(3):e2035353. doi: 10.25100/cm.v54i3.5353.
Kaderi M. A., Norberg M., Murray F. Merup M., Sundström C., Roos G., Aleskog A., Karlsson K., Axelsson T., Tobin G., Rosenquist R. // Leukemia. – 2008. – Vol. 22, № 2. – P. 339–343.
Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am. J. Clin. Pathol. 2015 May;143(5):635–44. doi: 10.1309/ AJCPUAAC16LIWZMM.
Kreuzberger N, Damen JA, Trivella M, Estcourt LJ, Aldin A, Umlauff L, Vazquez–Montes MD, Wolff R, Moons KG, Monsef I, Foroutan F, Kreuzer KA, Skoetz N. Prognostic models for newly–diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta–analysis. Cochrane Database Syst Rev. 2020 Jul 31;7(7):CD012022. doi: 10.1002/ 14651858.CD012022.pub2.
Künkele A, Grosse–Lordemann A, Schra-mm A, Eggert A, Schulte JH, Bachmann HS. The BCL2–938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. BMC Cancer. 2013 Oct 2;13:452. doi: 10.1186/1471–2407–13–452.
Kuszczak B, Wróbel T, Wicherska–Pawłowska K, Rybka J. The Role of BCL–2 and PD–1/PD–L1 Pathway in Pathogenesis of Myelodysplastic Syndromes. Int J Mol Sci. 2023 Mar 1;24(5):4708. doi: 10.3390/ijms24054708.
Maddali M, Kulkarni UP, Ravindra N, Arunachalam AK, Venkatraman A, Lionel S, Manipadam MT, Devasia AJ, Korula A, Fouzia NA, Abraham A, Srivastava A, George B, Balasubramanian P, Mathews V. Mutation Profile in BCR–ABL1–Negative Myeloproliferative Neoplasms: A Single–Center Experience From India. Hematol Oncol Stem Cell Ther. 2022 Jun 1;15(2):13–20. doi: 10.1016/j.hemonc.2021.03.002.
Moawadh MS, Mir R, Tayeb FJ, Asim O, Ullah MF. Molecular Evaluation of the Impact of Polymorphic Variants in Apoptotic (Bcl–2/Bax) and Proinflammatory Cytokine (TNF–α/IL–8) Genes on the Susceptibility and Progression of Myeloproliferative Neoplasms: A Case–Control Biomarker Study. Curr Issues Mol Biol. 2023 May 2;45(5):3933–3952. doi: 10.3390/cimb45050251.
Nann D, Fend F. Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics. Cancers (Basel). 2021 Jul 14;13(14):3528. doi: 10.3390/cancers13143528.
Park B.L., Kim L.H., Cheong H.S., Cho H.Y., Kim E.M., Shin H.D., Kim Y.–S., Lee C. Identification of variants in cyclin D1 (CCND1) and B–Cell CLL/lymphoma 2 (BCL2) J. Hum. Genet. 2004;49:449–454. doi: 10.1007/s10038–004–0173–0.
Safavi M, Monabati A, Safaei A, Mirtalebi MS, Faghih M. JAK2, CALR, and MPL Mutation Profiles in BCR–ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East. Iran J Pathol. 2021 Spring;16(2):190–194. doi: 10.30699/IJP.2021.136458.2495.
Shallis RM, Zeidan AM, Wang R, Podoltsev NA. Epidemiology of the Philadelphia Chromosome–Negative Classical Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America. 2021; 35(2):177–189. doi: 10.1016/j.hoc.2020.11 .005.
Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Adv Hematol. 2012; 2012:524308. doi: 10.1155/2012/524308.
Yao Z, Yang B, Liu Z, Li W, He Q, Peng X. Genetic polymorphisms of Bcl–2 promoter in cancer susceptibility and prognosis: a meta–analysis. Oncotarget. 2017 Apr 11;8(15):25270–25278. doi: 10.18632/oncotarget.15751.
Zhang X, Weng W, Xu W, Wang Y, Yu W, Tang X, Ma L, Pan Q, Wang J, Sun F. Role of Bcl–2 –938 C>A polymorphism in susceptibility and prognosis of cancer: a meta–analysis. Sci Rep. 2014 Nov 28;4:7241. doi: 10.1038/srep07241.